• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Surgical Management of Colorectal Liver Metastases: Prognostic Indicators and the Impact of RAS Mutation Status.

作者信息

Wei Steven H, Samp Leigh A

机构信息

MD Anderson Cancer Center, Houston, Texas.

出版信息

J Adv Pract Oncol. 2015 Sep-Oct;6(5):460-6. doi: 10.6004/jadpro.2015.6.5.6. Epub 2015 Sep 1.

DOI:10.6004/jadpro.2015.6.5.6
PMID:27069738
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4803463/
Abstract
摘要

相似文献

1
Surgical Management of Colorectal Liver Metastases: Prognostic Indicators and the Impact of RAS Mutation Status.结直肠癌肝转移的外科治疗：预后指标及RAS突变状态的影响
J Adv Pract Oncol. 2015 Sep-Oct;6(5):460-6. doi: 10.6004/jadpro.2015.6.5.6. Epub 2015 Sep 1.
2
Prognostic factors after resection of colorectal liver metastases following preoperative second-line chemotherapy: Impact of RAS mutations.术前二线化疗后结直肠癌肝转移灶切除术后的预后因素：RAS 突变的影响
Eur J Surg Oncol. 2016 Sep;42(9):1378-84. doi: 10.1016/j.ejso.2016.02.249. Epub 2016 Mar 5.
3
Relevance of Ki-67 antigen expression and K-ras mutation in colorectal liver metastases.Ki-67抗原表达及K-ras突变在结直肠癌肝转移中的相关性
Eur J Surg Oncol. 2001 Feb;27(1):80-7. doi: 10.1053/ejso.2000.1029.
4
Japanese experience with hepatic resection of KRAS-mutated colorectal liver metastases.日本关于KRAS突变型结直肠癌肝转移灶肝切除的经验。
Chin Clin Oncol. 2019 Oct;8(5):47. doi: 10.21037/cco.2019.08.07. Epub 2019 Sep 3.
5
RAS Mutation Clinical Risk Score to Predict Survival After Resection of Colorectal Liver Metastases.RAS 基因突变临床风险评分预测结直肠癌肝转移切除术后的生存。
Ann Surg. 2019 Jan;269(1):120-126. doi: 10.1097/SLA.0000000000002319.
6
Clinical significance and prognostic relevance of KRAS, BRAF, PI3K and TP53 genetic mutation analysis for resectable and unresectable colorectal liver metastases: A systematic review of the current evidence.KRAS、BRAF、PI3K和TP53基因突变分析对可切除和不可切除结直肠癌肝转移的临床意义及预后相关性：当前证据的系统评价
Surg Oncol. 2018 Jun;27(2):280-288. doi: 10.1016/j.suronc.2018.05.012. Epub 2018 May 8.
7
Tailoring ablation strategies for colorectal liver metastases based upon rat sarcoma viral oncogene mutation status.根据大鼠肉瘤病毒致癌基因突变状态制定结直肠癌肝转移的消融策略。
Chin Clin Oncol. 2019 Oct;8(5):51. doi: 10.21037/cco.2019.08.05. Epub 2019 Sep 6.
8
BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection.BRAF和RAS突变作为接受肝切除的转移性结直肠癌患者的预后因素
Br J Cancer. 2015 Jun 9;112(12):1921-8. doi: 10.1038/bjc.2015.142. Epub 2015 May 5.
9
Recent Advances in Chemotherapy and Surgery for Colorectal Liver Metastases.结直肠癌肝转移的化疗与手术最新进展
Liver Cancer. 2016 Nov;6(1):72-79. doi: 10.1159/000449349. Epub 2016 Nov 29.
10
BRAF mutation is a prognostic biomarker for colorectal liver metastasectomy.BRAF 突变是结直肠癌肝转移切除术的预后生物标志物。
J Surg Oncol. 2012 Aug 1;106(2):123-9. doi: 10.1002/jso.23063. Epub 2012 Feb 13.

引用本文的文献

1
MiR-384 inhibits human colorectal cancer metastasis by targeting KRAS and CDC42.微小RNA-384通过靶向KRAS和细胞分裂周期蛋白42抑制人结直肠癌转移。
Oncotarget. 2016 Dec 20;7(51):84826-84838. doi: 10.18632/oncotarget.12704.

本文引用的文献

1
From multidisciplinary to personalized treatment of colorectal liver metastases: 4 reasons to consider RAS.从结直肠癌肝转移的多学科治疗到个性化治疗：考虑RAS的4个理由
Cancer. 2013 Dec 1;119(23):4083-5. doi: 10.1002/cncr.28348. Epub 2013 Sep 19.
2
Incidence and prognostic impact of KRAS and BRAF mutation in patients undergoing liver surgery for colorectal metastases.结直肠癌肝转移患者行肝切除术的 KRAS 和 BRAF 基因突变的发生率和预后影响。
Cancer. 2013 Dec 1;119(23):4137-44. doi: 10.1002/cncr.28347. Epub 2013 Sep 19.
3
RAS mutation status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases.
RAS 基因突变状态可预测行肝切除术的结直肠癌肝转移患者的生存和复发模式。
Ann Surg. 2013 Oct;258(4):619-26; discussion 626-7. doi: 10.1097/SLA.0b013e3182a5025a.
4
Margin status remains an important determinant of survival after surgical resection of colorectal liver metastases in the era of modern chemotherapy.在现代化疗时代，结直肠肝转移手术后的生存仍然与切缘状态密切相关。
Ann Surg. 2013 Jun;257(6):1079-88. doi: 10.1097/SLA.0b013e318283a4d1.
5
Selection for hepatic resection of colorectal liver metastases: expert consensus statement.结直肠癌肝转移肝切除术的选择：专家共识声明。
HPB (Oxford). 2013 Feb;15(2):91-103. doi: 10.1111/j.1477-2574.2012.00557.x.
6
EGFR and downstream genetic alterations in KRAS/BRAF and PI3K/AKT pathways in colorectal cancer: implications for targeted therapy.结直肠癌中EGFR以及KRAS/BRAF和PI3K/AKT通路的下游基因改变：对靶向治疗的意义
Discov Med. 2012 Sep;14(76):207-14.
7
KRAS mutations in primary tumours and post-FOLFOX metastatic lesions in cases of colorectal cancer.结直肠癌原发肿瘤和 FOLFOX 治疗后转移病灶中的 KRAS 突变。
Br J Cancer. 2012 Jul 10;107(2):340-4. doi: 10.1038/bjc.2012.218. Epub 2012 May 22.
8
Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer.BRAF 突变和微卫星不稳定性对转移性结直肠癌转移模式和预后的影响。
Cancer. 2011 Oct 15;117(20):4623-32. doi: 10.1002/cncr.26086. Epub 2011 Mar 31.
9
High survival rate after two-stage resection of advanced colorectal liver metastases: response-based selection and complete resection define outcome.两阶段切除治疗晚期结直肠肝转移的高存活率：基于反应的选择和完全切除定义了结果。
J Clin Oncol. 2011 Mar 10;29(8):1083-90. doi: 10.1200/JCO.2010.32.6132. Epub 2011 Jan 24.
10
KRAS mutation is associated with lung metastasis in patients with curatively resected colorectal cancer.KRAS 突变与可切除结直肠癌患者的肺转移有关。
Clin Cancer Res. 2011 Mar 1;17(5):1122-30. doi: 10.1158/1078-0432.CCR-10-1720. Epub 2011 Jan 14.